Key clinical point: Certain patients with type 2 diabetes may gain significant cardiovascular benefits from dulaglutide.
Major finding: During a median 5.4 years, participants who took dulaglutide had a 12% lower risk of major adverse cardiovascular events (HR, 0.88; 95% CI, 0.79-0.99; P = .026).
Study details: Double-blind, randomized, placebo-controlled trial of dulaglutide (1.5 mg weekly) versus placebo in 9,901 patients with type 2 diabetes.
Disclosures: Eli Lilly funded the study. Three of the authors were employees of Eli Lilly, eight reported financial relationships with the company, five reported financial relationships with other firms, and the remaining authors reported no competing interests.
Gerstein HC et al. Lancet. 2019 Jun 10. doi: 10.1016/S0140-6736(19)31149-3.